Effects of hydroxychloroquine on proteinuria in membranous nephropathy
| Autor: | Yan-jiao Cheng, Fang Wang, Xu-yang Cheng, Xin Wang, Yi-miao Zhang, Zhao Cui, Gang Liu, Li-qiang Meng, Ming-Hui Zhao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Glomerulonephritis Membranous Gastroenterology law.invention Membranous nephropathy Randomized controlled trial law Internal medicine medicine Humans Adverse effect Autoantibodies Proteinuria biology business.industry Receptors Phospholipase A2 Autoantibody Hydroxychloroquine medicine.disease Blood pressure Nephrology biology.protein Female medicine.symptom Antibody business Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Nephrology. 35:1145-1157 |
| ISSN: | 1724-6059 |
| Popis: | BACKGROUND Many patients with primary membranous nephropathy have severe proteinuria unresponsive to optimized renin-angiotensin-aldosterone system inhibitors (RAASi). We evaluated the efficacy and safety of hydroxychloroquine as an adjunctive agent in membranous nephropathy (MN) treatments. METHODS We prospectively recruited 126 patients with biopsy-proven primary membranous nephropathy and urinary protein 1-8 g/day while receiving optimized RAASi treatment for ≥ 3 months and well-controlled blood pressure. Forty-three patients received hydroxychloroquine and RAASi (hydroxychloroquine-RAASi group), and 83 patients received RAASi alone (RAASi group). Treatment responses, including proteinuria reduction, complete and partial remission rates, and autoantibody against phospholipase A2 receptor (anti-PLA2R) levels, were compared between the two groups at 6 months and over the long term. RESULTS At 6 months, the effective response rate (proteinuria reduction > 30%) (57.5% vs. 28.9%, P = 0.002), clinical remission rate (35.0% vs. 15.7%, P = 0.015), and percentage change in proteinuria (- 51.7% vs. - 21.9%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink